SCHEMBL1279779

SCHEMBL1279779

CC(C)(C)OC(=O)N1CC[C@H]([C@@H](O)CO)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.46
GPR119 Q8TDV5 5/20 0.45
DPP4 P27487 1/20 0.44
HPGD P15428 1/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
RECQL P46063 1/20 0.43
EPHX1 P07099 1/20 0.43
EED O75530 1/20 0.42
RBBP4 Q09028 1/20 0.42
SUZ12 Q15022 1/20 0.42
EZH2 Q15910 1/20 0.42
AEBP2 Q6ZN18 1/20 0.42
IDO1 P14902 3/20 0.41
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PRMT5 O14744 1/20 0.40
WDR77 Q9BQA1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15265664 1.00 NR1H2 (0.46) NR1H2GPR119DPP4HPGDMEN1
SCHEMBL958699 1.00 NR1H2 (0.46) NR1H2GPR119DPP4HPGDMEN1
SCHEMBL958700 1.00 NR1H2 (0.46) NR1H2GPR119DPP4HPGDMEN1
SCHEMBL1279783 1.00 NR1H2 (0.46) NR1H2GPR119DPP4HPGDMEN1
SCHEMBL1059992 0.91 GPR119 (0.45) NR1H2GPR119DPP4HPGDMEN1
SCHEMBL1059994 0.91 GPR119 (0.45) NR1H2GPR119DPP4HPGDMEN1
SCHEMBL2546915 0.91 GPR119 (0.45) NR1H2GPR119DPP4HPGDMEN1
SCHEMBL1059077 0.91 GPR119 (0.45) NR1H2GPR119DPP4HPGDMEN1
SCHEMBL585825 0.91 GPR119 (0.45) NR1H2GPR119DPP4HPGDMEN1
SCHEMBL1059075 0.91 GPR119 (0.45) NR1H2GPR119DPP4HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000191-B2 Serotonin reuptake inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-04-07 US disclosed
US-9000191-B2 Serotonin reuptake inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-04-07 US disclosed
US-9000191-B2 Serotonin reuptake inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-04-07 US disclosed
EP-2627630-B1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE BIOPHARMA R & D IP LLC (US) 2014-12-31 EP disclosed
EP-2627630-B1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE BIOPHARMA R & D IP LLC (US) 2014-12-31 EP disclosed
US-20140243536-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2014-08-28 US disclosed
US-20140243536-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2014-08-28 US disclosed
US-20140243536-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2014-08-28 US disclosed
US-8729119-B2 Serotonin reuptake inhibitors THERAVANCE, INC. (US) 2014-05-20 US disclosed
US-8729119-B2 Serotonin reuptake inhibitors THERAVANCE, INC. (US) 2014-05-20 US disclosed
US-8471040-B2 Serotonin reuptake inhibitors THERAVANCE, INC. (US) 2013-06-25 US disclosed
US-8471040-B2 Serotonin reuptake inhibitors THERAVANCE, INC. (US) 2013-06-25 US disclosed
US-8471040-B2 Serotonin reuptake inhibitors THERAVANCE, INC. (US) 2013-06-25 US disclosed
WO-2012075239-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2012-06-07 WO disclosed
US-20120142689-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2012-06-07 US disclosed
US-20120142689-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2012-06-07 US disclosed
US-20120142689-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2012-06-07 US disclosed
US-20120088799-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2012-04-12 US disclosed
US-20120088799-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2012-04-12 US disclosed
US-20120088799-A1 SEROTONIN REUPTAKE INHIBITORS THERAVANCE, INC. (US) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088799-A1 SEROTONIN REUPTAKE INHIBITORS SLC6A4, SLC6A2, TPH1 NR1H2 1739/4885GPR119 628/4885DPP4 1987/4885
US-20120142689-A1 SEROTONIN REUPTAKE INHIBITORS SLC6A4, SLC6A2, TPH1 NR1H2 2150/4885GPR119 619/4885DPP4 2625/4885
US-20140243536-A1 SEROTONIN REUPTAKE INHIBITORS SLC6A4, SLC6A2, TPH1 NR1H2 1739/4885GPR119 628/4885DPP4 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.